Annovis Bio is developing a drug for Alzheimer's Disease, Parkinson's Disease and other neurodegenerative diseases that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport.
Location: United States, Pennsylvania, Berwyn
Total raised: $50M
Investors 2
| Date | Name | Website |
| - | BioAdvance | bioadvance... |
| - | Ben Frankl... | sep.benfra... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.05.2021 | - | $50M | - |
Mentions in press and media 12
| Date | Title | Description |
| 07.07.2026 | NYSE Content Update: Teradata AI Report Surveys 1,000 Global Tech + Data Leaders | NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, July 7, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pr... |
| 04.02.2025 | Annovis Bio, Inc. Announces Closing of $21 Million Public Offering | MALVERN, PA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- via IBN - Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alz... |
| 01.05.2023 | Money Moves: Motobyo launched two crowdfunding campaigns to raise $4M | Money Moves is a column where we chart the funding raises of tech companies across the region. Have a tip? Email us at philly@technical.ly. Motobyo seeks $4 million raise with crowdfunding campaigns Motobyo, the Horsham-based startup with a... |
| 13.01.2023 | Here are some interesting companies I met at JPM this week | Every year, MedCity News reporters receive scores of requests to meet promising companies that are hoping to solve major challenges in the U.S. healthcare system. 2023 was no different. Here are some companies I met this week in San Francis... |
| 09.01.2023 | Healthcare Hires of Note | ProofPilot, a digital protocol automation platform for clinical trials, has added Bernadette Tosti to its executive leadership team in the role of chief product officer this week. Tosti has more than 15 years of experience in the digital cl... |
| 15.11.2021 | Annovis Bio : November 15, 2021Annovis Bio Announces Transfer of Listing to the New York Stock Exchange | Mon, 15 Nov 2021 Trading to begin November 18, 2021 with current ticker "ANVS" BERWYN, PA., November 15, 2021 -- Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platf... |
| 05.10.2021 | Annovis Bio : October 5, 2021Annovis Bio Announces Positive Phase 2 Efficacy Data for the Treatment of Parkinson's Disease | Tue, 05 Oct 2021 Data Shows Statistically Significant Improvements in Speed and Motor Function in PD Patients Annovis Bio to Request Meeting with FDA on Next Steps in Clinical Development Investor Conference Call to be Hosted Tuesday, Octob... |
| 24.09.2021 | Annovis Bio : September 24, 2021Annovis Bio to Present at the Cantor Global Healthcare Conference | Fri, 24 Sep 2021 BERWYN, PA., September 24, 2021 -- Annovis Bio, Inc.(NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD... |
| 02.07.2021 | PACT held its annual Enterprise Awards IRL this week. Here’s who was honored | For the first time in about a year and a half, the Philadelphia Alliance for Capital and Technologies (PACT) gathered tech and healthcare innovators from across the region for an in-person event to celebrate the org’s annual Enterprise Awar... |
| 22.05.2021 | ANNOVIS BIO, INC. Annovis Bio : May 21, 2021Annovis Bio, Inc. Announces Proposed Public Offering of Common Stock | Fri, 21 May 2021 Berwyn, PA - May 21, 2021- Annovis Bio, Inc. (NASDAQ: ANVS) ('Annovis' or the 'Company') a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative disea... |
Show more